<DOC>
	<DOCNO>NCT00017576</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Calcitriol may help carboplatin kill cancer cell make tumor cell sensitive drug . PURPOSE : Phase II trial study effectiveness carboplatin plus calcitriol treating patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Calcitriol Carboplatin Treating Patients With Stage IV Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response patient androgen-independent prostate cancer treat calcitriol carboplatin . II . Determine palliative response patient cancer-related pain treat regimen . III . Determine response patient bidimensionally measurable disease treat regimen . IV . Determine duration prostate-specific antigen , palliative , measurable disease responses patient treated regimen . V. Determine survival patient treat regimen . VI . Assess quality life patient treat regimen . VII . Determine qualitative quantitative toxic effect regimen patient . OUTLINE : Patients receive oral calcitriol day 1 carboplatin IV 60 minute day 2 . Treatment repeat every 28 day absence unacceptable toxicity disease progression . Quality life assess baseline every 4 week disease progression . Patients follow every 4 week disease progression every 3 month thereafter . PROJECTED ACCRUAL : A total 18-36 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Stage IV Evidence progression despite standard hormonal management include antiandrogen withdrawal , define 1 follow : Development new metastatic lesion Increase cancerrelated pain A 50 % rise prostatespecific antigen ( PSA ) level confirm 2 measurement least 2 week apart PSA least 5 ng/mL Testosterone le 50 ng/mL PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.3 mg/dL Calcium great 10.5 mg/dL Phosphorus great 4.2 mg/dL No kidney stone within past 5 year No history cancerrelated hypercalcemia Cardiovascular : No uncontrolled heart failure Other : No malignancy within past 5 year except nonmelanoma skin cancer No significant active medical illness would preclude study Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 type prior chemotherapy prostate cancer No prior carboplatin cisplatin prostate cancer Endocrine therapy : See Disease Characteristics At least 4 week since prior flutamide nilutamide ( 6 week bicalutamide ) Concurrent primary hormonal therapy allow ( e.g. , gonadotropinreleasing hormone agonist antagonist ) Radiotherapy : At least 1 month since prior radiotherapy At least 2 month since prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium Surgery : Concurrent orchiectomy allow Other : At least 7 day since prior thiazide diuretic At least 30 day since prior investigational therapy No prior calcitriol prostate cancer No concurrent magnesiumcontaining antacid , bileresin binder , calcium supplement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>